Predictive Value of Soluble CD146 in Glioblastoma Patients

Recruiting now · Not applicable

Conditions studied: Glioblastoma

In brief

Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent and fails to enhance patients' overall survival. The investigators previously identified one novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022). Now, the investigators objective is to prospectively monitor the soluble CD146 value in plasma from patients treated by bevacizumab for recurrent glioblastoma. The investigators will collect plasma at baseline, before the first bevacizumab administration, before the second administration, at the time of first MRI evaluation and at progression. Plasma CD146 value will be analyzed by ELISA. The investigators expect to confirm the correlation between soluble CD146 value in plasma and patient response to bevacizumab.

Key facts

Study ID

NCT06001281

Run by

Assistance Publique Hopitaux De Marseille

People needed

55

Starts

2024-01-30

Expected to finish

2026-12-01

Last updated by the study team

2024-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• - Adult patients with recurrent IDHwt glioblastoma
• Relapse after standard first line treatment (radio-chemotherapy)
• Candidate for bevacizumab treatment
• Able to be monitored by MRI
• KPS ≥ 60%
• Written signed consent form

You may not qualify if…

• Pregnancy or breast feeding
• Life expectancy less than 3 months
• Bevacizumab in first line treatment
• Other concomitant life-threatening disease
• Under legal protection

Where it is running

• Service de Neuro-oncologie — Marseille, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.